And board member Rachel David was for many years the director of policy & government affairs for Johnson & Johnson in Australia, one of the biggest pharma and med tech commercialisers in the world. She knows her way around Canberra and the TGA, as well as how to build strong commercial partnerships - that’s J&J bread and butter.
Why isn't Colostat being sold into European markets and NZ?, page-16
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.001(1.00%) |
Mkt cap ! $24.61M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.6¢ | $24.87K | 251.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7155 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 113328 | 2 |
View Market Depth
| Last trade - 14.20pm 11/10/2024 (20 minute delay) ? |
| RHY (ASX) Chart |